Pharma BD Deal Intelligence

Gilead Sciences Inc. / Immunomedics Inc.

2020 · Acquisition/Merger · $21.0B · Complete

Announcement Sentiment

Strongly positive

Outcome Score

Largely worked — most objectives met.

Gilead Sciences acquired Immunomedics for approximately $21 billion ($88.00 per share in cash), a 108% premium, gaining Trodelvy (sacituzumab govitecan), the first FDA-approved anti-Trop-2 antibody-drug conjugate for metastatic triple-negative breast cancer, along with Immunomedics' proprietary ADC platform technology.

Key facts

Announced Sep 13, 2020
Closed Oct 23, 2020
Deal value $21.0B
Deal type Acquisition/Merger
Therapeutic area Oncology
Indications Triple-Negative Breast Cancer, Urothelial Cancer
Key assets sacituzumab govitecan (Trodelvy), Trop-2 ADC platform
Mechanism Anti-Trop-2 antibody-drug conjugate

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals